Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L9XS
|
|||
| Former ID |
DIB000807
|
|||
| Drug Name |
Plasmin
|
|||
| Synonyms |
Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke); Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke), Talecris Biotherapeutics
Click to Show/Hide
|
|||
| Indication | Occlusive disease [ICD-11: BD4Z; ICD-10: I66.9] | Phase 2 | [1] | |
| Peripheral arterial disease [ICD-11: BD4Z; ICD-10: I73, I73.9] | Phase 2 | [2] | ||
| Company |
Grifols therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibrin (FG) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021318) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01014975) A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.